Date: 2014-09-30
Type of information: Milestone
Compound: Wnt inhibitor
Company: Bayer HealthCare (Germany) OncoMed Pharmaceuticals (USA)
Therapeutic area: Cancer Oncology
Type agreement: development manufacturing production
Action mechanism:
Disease:
Details: * On April 21, 2011, OncoMed Pharmaceuticals has expanded its collaboration with Bayer HealthCare. Bayer\'s U.S. affiliate will manufacture clinical supplies of a second Wnt inhibitor in the alliance. Bayer will manufacture the bulk drug substance at its Berkeley, California clinical manufacturing center to support Phase 1 clinical testing planned to commence in 2012. This is an addition to OncoMed\'s existing relationship with Bayer. In June 2010, OncoMed and Bayer HealthCare entered into a broad strategic alliance valued at up to $387.5M per program, plus potential double-digit royalties, to develop cancer stem cell antibody and protein therapeutics targeting the Wnt signaling pathway. The first program from the collaboration, antibody therapeutic product candidate OMP-18R5, is expected to enter clinical testing in 2011. Financial terms of the manufacturing agreement were not disclosed, and this agreement does not alter any of the financial terms of the original collaboration.
As part of the existing collaboration, Bayer has the option to license OncoMed\'s biologics in the Wnt pathway at any point through the completion of Phase 1 studies. In addition, Bayer and OncoMed are working together to discover small molecule Wnt signaling inhibitors as part of the collaboration.
Financial terms:
Latest news: * On September 30, 2014, OncoMed Pharmaceuticals announced the advancement of the first small molecule Wnt pathway inhibitor under its collaboration with Bayer Pharma. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed. This is the first small molecule inhibitor of a cancer stem cell pathway from the collaboration to enter preclinical development. Bayer will lead development and commercialization of Wnt small molecule product candidates. As part of this collaboration, OncoMed is leading the advancement of two clinical-stage biologic candidates, vantictumab (anti-FZD7, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28), through multiple Phase 1b studies.
